Results 11 to 20 of about 8,266,387 (310)

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

Nature Medicine, 2023
The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid tumors, and could be a promising treatment target. We report dose escalation results from the ongoing phase 1/2 BNT211-01 trial evaluating the safety and ...
A. Mackensen, J. Haanen, C. Koenecke, W. Alsdorf, E. Wagner-Drouet, P. Borchmann, D. Heudobler, B. Ferstl, S. Klobuch, Carsten Bokemeyer, A. Desuki, F. Lüke, N. Kutsch, F. Müller, E. Smit, P. Hillemanns, P. Karagiannis, E. Wiegert, Ying He, T. Ho, Q. Kang-Fortner, A. M. Schlitter, C. Schulz-Eying, Andrew Finlayson, C. Flemmig, K. Kühlcke, L. Preußner, B. Rengstl, O. Türeci, U. Şahin   +29 more
semanticscholar   +1 more source

HIF-1α drives resistance to ferroptosis in solid tumors by promoting lactate production and activating SLC1A1.

Cell Reports, 2023
Solid tumors have developed robust ferroptosis resistance. The mechanism underlying ferroptosis resistance regulation in solid tumors, however, remains elusive.
Zhou Yang, Wei Su, Xiyi Wei, Shuang Qu, Dan Zhao, Jingwan Zhou, Yun-Jun Wang, Qing Guan, Chao Qin, Jun Xiang, Zen Ke, Bing Yao   +11 more
semanticscholar   +1 more source

Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood

Bioengineering & Translational Medicine, 2022
The analysis of circulating tumor cells (CTCs) in blood is a powerful noninvasive alternative to conventional tumor biopsy. Inertial‐based separation is a promising high‐throughput, marker‐free sorting strategy for the enrichment and isolation of CTCs ...
Alejandro Rodríguez‐Pena, Estibaliz Armendariz, Alvaro Oyarbide, Xabier Morales, Sergio Ortiz‐Espinosa, Borja Ruiz‐Fernández de Córdoba, Denis Cochonneau, Iñaki Cornago, Dominique Heymann, Josepmaría Argemi, Delia D'Avola, Bruno Sangro, Fernando Lecanda, Ruben Pio, Iván Cortés‐Domínguez, Carlos Ortiz‐de‐Solórzano   +15 more
doaj   +1 more source

Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade

Science, 2017
Predicting responses to immunotherapy Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have favorable responses to PD-1 blockade immunotherapy. In a phase 2 clinical trial, Le et al.
Dung T. Le, Jennifer N. Durham, Kellie N. Smith, Hao Wang, Bjarne R. Bartlett, Laveet K. Aulakh, Steve Lu, H. Kemberling, C. Wilt, Brandon S. Luber, F. Wong, N. Azad, A. Rucki, D. Laheru, R. Donehower, A. Zaheer, G. Fisher, T. Crocenzi, James J. Lee, T. Greten, A. Duffy, K. Ciombor, A. Eyring, B. Lam, A. Joe, S. Kang, M. Holdhoff, Ludmila V. Danilova, L. Cope, C. Meyer, Shi-Bin Zhou, R. Goldberg, D. Armstrong, Katherine M. Bever, A. Fader, J. Taube, F. Housseau, D. Spetzler, N. Xiao, D. Pardoll, N. Papadopoulos, K. Kinzler, J. Eshleman, B. Vogelstein, R. Anders, L. Diaz   +45 more
semanticscholar   +1 more source

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment

Experimental Hematology & Oncology, 2023
The past decade has witnessed ongoing progress in immune therapy to ameliorate human health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the advantages of specific killing of cancer cells, a high remission rate of cancer ...
Ting Yan, Lingfeng Zhu, Jin Chen
semanticscholar   +1 more source

Key chemokines direct migration of immune cells in solid tumors

Cancer Gene Therapy, 2021
Immune cell infiltration into solid tumors, their movement within the tumor microenvironment (TME), and interaction with other immune cells are controlled by their directed migration towards gradients of chemokines.
Karan Kohli, V. Pillarisetty, Teresa S. Kim   +2 more
semanticscholar   +1 more source

FDA Approval Summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors

Clinical Cancer Research, 2021
The FDA approved pembrolizumab on June 16, 2020, for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden–high [TMB-H; ≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test ...
L. Marcus, L. Fashoyin-Aje, Martha Donoghue, Mengdie Yuan, Lisa R Rodriguez, Pamela S. Gallagher, Reena Philip, Soma Ghosh, M. Theoret, J. Beaver, R. Pazdur, S. Lemery   +11 more
semanticscholar   +1 more source

A molecular map of mesenchymal tumors [PDF]

, 2005
Background: Bone and soft tissue tumors represent a diverse group of neoplasms thought to derive from cells of the mesenchyme or neural crest. Histological diagnosis is challenging due to the poor or heterogenous differentiation of many tumors, resulting
Flanagan, AM, Guiliano, D, Boshoff, C, McLean, S, Frow, R, Sebire, N, Henderson, SR, Stephen R Henderson, Nick Athanasou, Vujovic, S, Anderson, J, Athanasou, N, John Anderson, Neil Sebire, David Guiliano, Sean McLean, Nadege Presneau, Richard Frow, Jeremy Whelan, Whelan, J, Adrienne M Flanagan, Presneau, N, Sonja Vujovic, Chris Boshoff   +23 more
core   +1 more source

Modeling the Mechanobiology of Cancer Cell Migration Using 3D Biomimetic Hydrogels

Gels, 2021
Understanding how cancer cells migrate, and how this migration is affected by the mechanical and chemical composition of the extracellular matrix (ECM) is critical to investigate and possibly interfere with the metastatic process, which is responsible ...
Xabier Morales, Iván Cortés-Domínguez, Carlos Ortiz-de-Solorzano   +2 more
doaj   +1 more source

t(12;15)(p13;q25) ETV6/NTRK3 in solid tumors [PDF]

, 2020
Review on t(12;15)(p13;q25) in solid tumors, with data on clinics, and the genes ...
Huret, Jean-Loup
core   +1 more source